Hideko Yamauchi, MD, FACS
Director of Clinical Affairs, University of Hawaiʻi Cancer Center
Associate Member, Cancer Biology Program, Translational and Clinical Research, University of Hawaiʻi Cancer Center
Academic Appointment(s):
Professor (Researcher), University of Hawaiʻi Cancer Center, University of Hawaiʻi at Mānoa
Degree(s):
MD, Juntendo University School of Medicine
Honor(s)
Alpha Omega Alpha House Staff 2006 Honor Medical Society Alpha Chapter of Hawaiʻi
Award(s)
2012 September 19-21 - The 32nd European Society of Surgical Oncology, Best Video Award, ESSO 32 Congress, Valencia, Spain
2009 & 2010 - Finalist, International Ethic Research Initiative, (GSK)
2002 August - 2nd place, Resident Research Essay Contest Finals, American College of Surgeons, Hawaiʻi Chapter
Research Focus
Breast cancer, survivorship, genetics
Selected Publications
Yamauchi H, Toi M, Takayama S, Nakamura S, Takano T, Cui K, Campbell C, De Vos L, Geyer Jr C, Tutt A. (2023). Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast Cancer. 30:596-605.
Komatsu H, Yagasaki K, Yamauchi H. (2018). Fertility Decision-Making Under Certainty and Uncertainty in Cancer Patients. Sexual & Reproductive Healthcare. Mar; 15:40-45. doi:10.1016/j.srhc.2017.12.002. Epub 2017 Dec 7.
Yamauchi H, Okawa M, Yokoyama S, Nakagawa C, Yoshida R, Suzuki K, Nakamura S, Arai M. (2018). High Rate of Occult Cancer Found in Prophylactic Mastectomy Specimens Despite Thorough Pre-surgical Assessment with MRI and Ultrasound: Findings From the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan. Breast Cancer Research and Treatment 172 (3); 679-687: 2018 doi: 10. 1007/s10549-018-4953-1.
Yamauchi H, Nakagawa C, Fukuda T. (2017). Social impacts of the work loss in cancer survivors. Breast Cancer. Sep; 24 (5):694-701. doi:10.1007/s12282-017-0759-y. Epub 2017 Feb 16.
Natori A, Ogata T, Sumitani M, Kogure T, Yamauchi T, Yamauchi H. (2015) Potential Role of pNF-H, a Biomarker of Axonal Damage in the Central Nervous System, as a Predictive Marker of Chemotherapy-Induced Cognitive Impairment. Clin Cancer Res, 21(6):1348-52. Mar 15. Epub Jan 14, 2015.
